Tempus AI data business undervalued versus sum of parts

Conviction: 55% · Horizon: 2Y · 2026-07-27
Tempus data franchise alone is worth more than the equity, implying material undervaluation of the whole company

Management states that spinning out the data business on normal public-market terms would likely value that segment above the current market capitalization of the parent. That implies the market is not fully pricing the proprietary clinical and molecular dataset, while the diagnostics and AI platforms still carry optionality. A sum-of-parts re-rating, clearer data monetization metrics, or a structural separation could unlock value.

Instrument Side Target Reason
TEM Long We believe the market is still pricing Tempus primarily as a diagnostics/AI growth story and underweights the scarcity value of its longitudinal clinical-molecular dataset. If management is right that a standalone data IPO would exceed the current equity value, owning TEM is an asymmetric way to capture a sum-of-parts gap as data revenue visibility improves.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.